This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Eflornithine, difluoromethylornithine, DFMO
Description: Eflornithine is an orally bioavailable compound that has demonstrated the ability to block ornithine decarboxylase, an enzyme that is known to promote carcinogenesis. The drug is currently in a randomized, placebo-controlled phase III trial to evaluate the ability of Eflornithine to prevent the recurrence of superficial bladder cancer. The endpoint of this trial is the number of recurrences. Eflornithine will need to demonstrate a statistically significant reduction in the number of recurrences vs. placebo. The trial will end when an undisclosed number of recurrences have occurred. At that time the arms will be unblinded and compared.Ilex has stated that it is their intention to partner this product if the phase III data is positive. Bladder cancer is treated by urologists and not oncologists and this puts Eflornithine outside of the company's strategic focus.
Deal Structure: In October 2010, Sanofi-aventis announced it has commenced a tender offer for all outstanding shares of common stock of Genzyme for $69 per share, net to the seller in cash, without interest and less any required withholding taxes. In April 2011, Sanofi-aventis announced that it successfully completed its exchange offer for all outstanding shares of common stock of Genzyme Corporation.
Eflornithine (Sanofi) News
Additional information available to subscribers only: